Drug intelligence / Profile preview

c-RGDKYQ

Development stage: Preclinical
Lead developer: Medical College of Wisconsin
Modality: Cyclic Peptides → Modified Peptides → Peptides
Administration: Peri-tumoral Injection

Overview

c-RGDKYQ is a synthetic cyclic peptide designed for targeted melanoma therapy. It leverages the overexpression of tyrosinase in melanoma cells to trigger enzyme-mediated oxidation and self-assembly into nanostructures. These structures selectively disrupt actin cytoskeleton dynamics in melanoma cells, leading to impaired motility, adhesion, and proliferation, ultimately inducing apoptosis. The drug displays high tumor selectivity and minimal systemic toxicity in animal models and does not use external drug payloads or complex delivery systems, relying solely on the peptide's own pharmacodynamic properties[1].

Targets

TYR (Tyrosinase)

Beyond the preview

Go deeper on c-RGDKYQ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on c-RGDKYQ.

Explore the full profile